Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural motifs

Abstract

A vaccine composition is disclosed that comprises polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for preventing infection caused by S. pneumoniae comprising administering of vaccine compositions.

1 - 3 . (canceled)  
     
     
         4 . A vaccine comprising a first and a second polypeptide, wherein the first polypeptide comprises an active fragment of SEQ ID NO:4, wherein said active fragment comprises at least two coiled coil regions.  
     
     
         5 . The vaccine of  claim 4  wherein the first and the second polypeptide are fused together as a fusion protein.  
     
     
         6 . The vaccine of  claim 5  wherein the first polypeptide further comprises at least one histidine triad region.  
     
     
         7 . The vaccine of  claim 5  wherein the second polypeptide is selected from the group consisting of: 
 (a) a polypeptide comprising an amino acid sequence at least 95% identical to amino acid residues 21-480 of SEQ ID NO:6;    (b) a polypeptide comprising an amino acid sequence at least 97% identical to amino acid residues 21-480 of SEQ ID NO:6;    (c) a polypeptide comprising the amino acid sequence of amino acid residues 21-480 of SEQ ID NO:6;    (d) a polypeptide comprising an amino acid sequence at least 90% identical to amino acid residues 20-819 of SEQ ID NO:8;    (e) a polypeptide comprising the amino acid sequence of amino acid residues 20-819 of SEQ ID NO:8;    (f) a polypeptide comprising an amino acid sequence at least 90% identical to amino acid residues 20-819 of SEQ ID NO:10; and    (g) a polypeptide comprising the amino acid sequence of amino acid residues 20-819 of SEQ ID NO:10.    
     
     
         8 . The vaccine of  claim 7  wherein the second polypeptide is (a).  
     
     
         9 . The vaccine of  claim 7  wherein the second polypeptide is (b).  
     
     
         10 . The vaccine of  claim 7  wherein the second polypeptide is (c).  
     
     
         11 . The vaccine of  claim 5  wherein the second polypeptide is an active fragment of SEQ ID NO:6, wherein the active fragment comprises five histidine triad regions.  
     
     
         12 . A vaccine comprising a first and a second polypeptide, wherein the first polypeptide comprises an amino acid sequence at least 95% identical to amino acid residues 20-838 of SEQ ID NO:4.  
     
     
         13 . The vaccine of  claim 12  wherein the first and the second polypeptide are fused together as a fusion protein.  
     
     
         14 . The vaccine of  claim 13  wherein the first polypeptide comprises an amino acid sequence at least 97% identical to amino acid residues 20-838 of SEQ ID NO:4.  
     
     
         15 . The vaccine of  claim 14  wherein the first polypeptide comprises the amino acid sequence of amino acid residues 20-838 of SEQ ID NO:4.  
     
     
         16 . The vaccine of  claim 13  wherein the second polypeptide is selected from the group consisting of: 
 (a) a polypeptide comprising an amino acid sequence at least 95% identical to amino acid residues 21-480 of SEQ ID NO:6;    (b) a polypeptide comprising an amino acid sequence at least 97% identical to amino acid residues 21-480 of SEQ ID NO:6;    (c) a polypeptide comprising the amino acid sequence of amino acid residues 21-480 of SEQ ID NO:6;    (d) a polypeptide comprising an amino acid sequence at least 90% identical to amino acid residues 20-819 of SEQ ID NO:8;    (e) a polypeptide comprising the amino acid sequence of amino acid residues 20-819 of SEQ ID NO:8;    (f) a polypeptide comprising an amino acid sequence at least 90% identical to amino acid residues 20-819 of SEQ ID NO:10; and    (g) a polypeptide comprising the amino acid sequence of amino acid residues 20-819 of SEQ ID NO:10.    
     
     
         17 . The vaccine of  claim 16  wherein the second polypeptide is (a).  
     
     
         18 . The vaccine of  claim 16  wherein the second polypeptide is (b).  
     
     
         19 . The vaccine of  claim 16  wherein the second polypeptide is (c).  
     
     
         20 . The vaccine of  claim 16  wherein the second polypeptide is an active fragment of SEQ ID NO:6, wherein the active fragment comprises five histidine triad regions.  
     
     
         21 . A method of eliciting an immune response to  Streptococcus pneumoniae  in a mammal comprising: 
 administering the vaccine of  claim 4  to said mammal.    
     
     
         22 . A method of eliciting an immune response to  Streptococcus pneumoniae  in a mammal comprising: 
 administering the vaccine of  claim 12  to said mammal.